How does eculizumab work in neuromyelitis optica spectrum disorder (NMOSD)?

Aug 15, 2018 ... Reported relapse rates in aHUS after stopping eculizumab are as high as 30%, suggesting indefinite therapy is reasonable and that patients who choose to stop ... Dec 12, 2022 ... It may be given to your child for other reasons. Talk with the doctor. Eculizumab. 2/11. Page 3 ... Feb 12, 2025 ... These studies suggest that eculizumab and ravulizumab are safe and effective treatments for people with AQP4-Ab+ NMOSD. See full prescribing information for. SOLIRIS. SOLIRIS® (eculizumab) injection, for intravenous use. Initial U.S. Approval: 2007. WARNING: SERIOUS MENINGOCOCCAL ... Sep 21, 2024 ... Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and myasthenia gravis. 2. How ... Apr 6, 2025 ... Eculizumab, a humanized anti-C5 monoclonal antibody, has been the standard of care for treating aHUS, and has been shown to be effective in ... The SOLIRIS Infusion Finder provides access to a locator tool, which shows sites providing infusion services. Eculizumab is a humanized monoclonal antibody directed against C5 of the complement cascade and thereby inhibits the formation of C5a and C5b-9 membrane attack ... Your browsing activity is empty. Activity recording is turned off. Turn recording back on. See more... Follow NCBI. Connect with NLM. National Library of ... Jul 27, 2023 ... Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to include the treatment of refractory generalised myasthenia ...